Literature DB >> 18473457

Inhibition of HIV fusion with multivalent gold nanoparticles.

Mary-Catherine Bowman1, T Eric Ballard, Christopher J Ackerson, Daniel L Feldheim, David M Margolis, Christian Melander.   

Abstract

The design and synthesis of a multivalent gold nanoparticle therapeutic is presented. SDC-1721, a fragment of the potent HIV inhibitor TAK-779, was synthesized and conjugated to 2.0 nm diameter gold nanoparticles. Free SDC-1721 had no inhibitory effect on HIV infection; however, the (SDC-1721)-gold nanoparticle conjugates displayed activity comparable to that of TAK-779. This result suggests that multivalent presentation of small molecules on gold nanoparticle surfaces can convert inactive drugs into potent therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473457      PMCID: PMC2916654          DOI: 10.1021/ja710321g

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  12 in total

1.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Authors:  Jacqueline D Reeves; Stephen A Gallo; Navid Ahmad; John L Miamidian; Phoebe E Harvey; Matthew Sharron; Stefan Pohlmann; Jeffrey N Sfakianos; Cynthia A Derdeyn; Robert Blumenthal; Eric Hunter; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

2.  A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.

Authors:  M Baba; O Nishimura; N Kanzaki; M Okamoto; H Sawada; Y Iizawa; M Shiraishi; Y Aramaki; K Okonogi; Y Ogawa; K Meguro; M Fujino
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

3.  A thermodynamic investigation into the binding properties of DNA functionalized gold nanoparticle probes and molecular fluorophore probes.

Authors:  Abigail K R Lytton-Jean; Chad A Mirkin
Journal:  J Am Chem Soc       Date:  2005-09-21       Impact factor: 15.419

Review 4.  Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.

Authors:  Giuseppe Barbaro; Andrea Scozzafava; Antonio Mastrolorenzo; Claudiu T Supuran
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

Review 5.  Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors.

Authors:  Mathai Mammen; Seok-Ki Choi; George M Whitesides
Journal:  Angew Chem Int Ed Engl       Date:  1998-11-02       Impact factor: 15.336

6.  An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry.

Authors:  Diana Safarian; Xavier Carnec; Fotini Tsamis; Francis Kajumo; Tatjana Dragic
Journal:  Virology       Date:  2006-06-14       Impact factor: 3.616

7.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 8.  The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection.

Authors:  John P Moore; Scott G Kitchen; Pavel Pugach; Jerome A Zack
Journal:  AIDS Res Hum Retroviruses       Date:  2004-01       Impact factor: 2.205

9.  Hybridization and enzymatic extension of au nanoparticle-bound oligonucleotides.

Authors:  Sheila R Nicewarner Peña; Surabhi Raina; Glenn P Goodrich; Nina V Fedoroff; Christine D Keating
Journal:  J Am Chem Soc       Date:  2002-06-26       Impact factor: 15.419

10.  Structure of a thiol monolayer-protected gold nanoparticle at 1.1 A resolution.

Authors:  Pablo D Jadzinsky; Guillermo Calero; Christopher J Ackerson; David A Bushnell; Roger D Kornberg
Journal:  Science       Date:  2007-10-19       Impact factor: 47.728

View more
  94 in total

1.  Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation.

Authors:  Dan Zheng; David A Giljohann; David L Chen; Matthew D Massich; Xiao-Qi Wang; Hristo Iordanov; Chad A Mirkin; Amy S Paller
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-06       Impact factor: 11.205

Review 2.  The gold-sulfur interface at the nanoscale.

Authors:  Hannu Häkkinen
Journal:  Nat Chem       Date:  2012-05-22       Impact factor: 24.427

Review 3.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

Review 4.  Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies.

Authors:  Hamed Haddad Kashani; Mathias Schmelcher; Hamed Sabzalipoor; Elahe Seyed Hosseini; Rezvan Moniri
Journal:  Clin Microbiol Rev       Date:  2017-11-29       Impact factor: 26.132

Review 5.  Translational challenges in targeting latent HIV infection and the CNS reservoir problem.

Authors:  Carolina Garrido; David M Margolis
Journal:  J Neurovirol       Date:  2014-07-25       Impact factor: 2.643

Review 6.  The role of nanotechnology in the treatment of viral infections.

Authors:  Lavanya Singh; Hendrik G Kruger; Glenn E M Maguire; Thavendran Govender; Raveen Parboosing
Journal:  Ther Adv Infect Dis       Date:  2017-07-05

7.  Multimodal gadolinium-enriched DNA-gold nanoparticle conjugates for cellular imaging.

Authors:  Ying Song; Xiaoyang Xu; Keith W MacRenaris; Xue-Qing Zhang; Chad A Mirkin; Thomas J Meade
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

Review 8.  Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections.

Authors:  Tejabhiram Yadavalli; Deepak Shukla
Journal:  Nanomedicine       Date:  2016-08-26       Impact factor: 5.307

9.  Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release.

Authors:  Amit K Jha; Weidong Yang; Catherine B Kirn-Safran; Mary C Farach-Carson; Xinqiao Jia
Journal:  Biomaterials       Date:  2009-09-23       Impact factor: 12.479

Review 10.  Progress in antiretroviral drug delivery using nanotechnology.

Authors:  Rama Mallipeddi; Lisa Cencia Rohan
Journal:  Int J Nanomedicine       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.